Sunshine Biopharma, Inc. — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013. Sunshine Biopharma was a development-stage pharmaceutical company focused on cancer-drug research and development. The interim financial statements were unaudited.
Financial results and position
| Metric | Q1 2013 / March 31, 2013 | Comparable period / December 31, 2012 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2012 |
| Operating expenses | $922,891 | $39,325 in Q1 2012 |
| Operating loss | $922,891 | $39,325 in Q1 2012 |
| Net loss | $1,477,172; $0.03 per basic share | $39,341 in Q1 2012 |
| Cash and cash equivalents | $255,917 | $132,638 at December 31, 2012 |
| Total current assets | $258,955 | $134,793 at December 31, 2012 |
| Total liabilities | $22,354 | $64,367 at December 31, 2012 |
| Shareholders’ equity | $236,601 | $70,426 at December 31, 2012 |
| Net cash used in operations | $339,721 | $34,757 in Q1 2012 |
| Net cash from financing | $463,000 | $12,500 in Q1 2012 |
No profit margin is meaningful because the company reported no revenue. Cash provided by financing exceeded operating cash use, and cash increased by $123,279 during the quarter. The filing reports no investing cash flows. It does not provide a clear cash-runway estimate.
Material changes and unusual items
- Operating expenses rose by $883,566 year over year. The largest reported costs were financial consulting ($622,610) and licensing fees ($250,000); research and development expense was $23,400.
- Net loss included $548,951 of noncash interest expense for a beneficial conversion feature on convertible notes. The filing separately reports $5,330 of interest expense.
- The company issued 4,772,969 common shares during the quarter, including shares for services and conversion of notes. Outstanding shares increased from 51,416,092 at December 31, 2012 to 56,189,061 at March 31, 2013.
- Convertible notes with reported aggregate principal of $513,000, bearing 6% interest and convertible at $0.20 per share, were converted in March. A separate $12,500 note payable remained outstanding at March 31, accruing interest at 12%; accrued interest was $1,516. Current portion of note payable declined from $62,500 at year-end.
Business outlook, risks, and controls
The company’s lead candidate, Adva-27a, had completed preclinical studies. Planned next steps included GMP manufacturing, IND-enabling studies, regulatory filing, and Phase I trials for multidrug-resistant breast cancer. Management anticipated Phase I trials in mid-to-late 2014 and completion by late 2015, but these were forward-looking plans, not commitments. The company stated that it needed approximately $5 million in debt and/or equity funding to implement its plan, had no committed financing, and lacked sufficient funds for anticipated increases in research, development, and clinical-trial costs. It warned that failure to obtain financing could materially harm operations and financial condition.
The filing identifies clinical, regulatory, financing, and commercialization uncertainty; it gives no assurance of trial success, compassionate-use approval, or a licensing or sale transaction. Management said disclosure controls were effective at the reasonable-assurance level and reported no material changes in internal control over financial reporting. No legal proceedings or defaults upon senior securities were reported.
Important facts for investors to verify
- Reconcile the share counts for the March note conversion: the filing gives differing figures in different sections (including 2,590,426, 2,590,428, and 2,590,248 shares).
- Confirm the accounting and classification of the $548,951 beneficial conversion feature: it appears as other expense in the statements, while MD&A also refers to it among general and administrative expense drivers.
- Check the comparative cash-flow period: the table of contents refers to 2011 in one place, while the statements and MD&A identify Q1 2012.
- Assess financing availability against the stated approximately $5 million funding requirement, cash balance, and ongoing cash burn.
- Track progress and funding for GMP manufacturing, IND-enabling work, regulatory submissions, and the proposed Phase I program; timelines and potential approvals remain uncertain.